BiotechTube

RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placebo

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriatic Subjects

Conditions

Psoriatic Subjects

Trial Timeline

Apr 1, 2025 → Mar 1, 2026

NCT ID
NCT06918743

About RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placebo

RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placebo is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Psoriatic Subjects. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06918743. Target conditions include Psoriatic Subjects.

What happened to similar drugs?

10 of 20 similar drugs in Psoriatic Subjects were approved

Approved (10) Terminated (0) Active (10)
✅Ixekizumab + AdalimumabEli LillyApproved
✅TirzepatideEli LillyApproved
✅GuselkumabJohnson & JohnsonApproved
✅methotrexate (MTX) + adalimumab (ADA)AbbVieApproved
✅Upadacitinib 15 MG [Rinvoq] + PlaceboAbbVieApproved
✅Secukinumab 300 mg + Secukinumab 150 mgNovartisApproved
✅ApremilastAmgenApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06918743Phase 2Recruiting

Competing Products

20 competing products in Psoriatic Subjects

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + TirzepatideEli LillyPre-clinical
33
Ixekizumab + TirzepatideEli LillyPhase 3
44
Ixekizumab + AdalimumabEli LillyApproved
43
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
35
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
38
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
44
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
35
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
40
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
44
Ixekizumab + AdalimumabEli LillyPhase 3
44
TirzepatideEli LillyApproved
50
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
40
GuselkumabJohnson & JohnsonApproved
50
SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
36